Multiple Sclerosis Relapse News Today

Measuring levels of neurofilament light chain in the blood could warn of worsening disability up to 2 years before it occurs.

COVID-19 has no impact on disease activity, progression, or cognitive performance in patients with multiple sclerosis.

Anti-CD20 antibody therapy can be effectively and safely administered subcutaneously to patients with MS, even when switching from a prior treatment, two clinical trials suggest.

A smartwatch and sophisticated artificial intelligence to analyze data could open a new frontier in monitoring disease progression, researchers say.

Measuring the thickness of the retina shortly after diagnosis in multiple sclerosis patients could predict their risk of accumulated disability later in the disease course, say Austrian researchers.

The relapse rate among patients with relapsing-remitting multiple sclerosis who were treated with rituximab was higher than among those treated with ocrelizumab, results of a noninferiority study suggest.

Phase 2 data on the investigational drug frexalimab show favorable safety and significant reduction in new T1 brain lesions in relapsing MS.

"Serious infections did not vary by age, and there were too few serious events to identify any age-related trends by specific TEAE," the authors reported.

Contrary to previous research, a new study suggests fertility treatments pose little risk of MS relapse in women who undergo fertility treatments, suggesting it may be time for new clinical guidance.

Since the emergence of the first therapy, more than 20 agents with moderate to high efficacy have come to market for relapsing multiple sclerosis – but experts say thats both a blessing and problem.